Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$2.61 ▲ +0.02
(+0.77%)
MKT CAP: $210.3M • VOL: 274.8K
52W L $2 52W H $3
PLX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $52.7M | $53.4M | $65.5M |
| YoY Revenue Growth % | -1.2% | -18.5% | — |
| Gross Profit | $25.8M | $29.1M | — |
| Gross Margin % | 48.8% | 54.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$5.5M | $3.9M | $10.5M |
| Operating Margin % | -10.4% | 7.3% | 16.0% |
| Net Income (GAAP) | -$6.6M | $2.9M | $8.3M |
| EBITDA (Normalized) | -$4.2M | $4.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$12.0M | $8.7M | -$1.3M |
| Capital Expenditures (CapEx) | $1.6M | $1.3M | — |
| Free Cash Flow (FCF) | -$13.6M | $7.4M | -$1.3M |
| FCF Margin % | -25.8% | 13.8% | -2.0% |
| Return on Invested Capital (ROIC %) | -13.0% | 13.2% | — |
| Cash & Short-Term Equivalents | $14.7M | $19.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $48.2M | $43.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PLX.